The key to increasing US pharmaceutical supply chain resiliency is to make the global supply chain publicly transparent, a National Academies of Science, Engineering and Medicine expert committee concluded in a 3 March report.
That means the US Food and Drug Administration should enhance awareness of possible shortcomings of the supply chain by publicizing sourcing, quality, volume and capacity information for all pharmaceutical and other medical products approved or cleared for sale in the